Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Fig. 1

OS according to ERCC1 expression. Patients with moderate or high levels of ERCC1 had shorter overall survival [median OS: 10.5 months mean OS ± SE: 12.5 months ±1.9 (95% CI: 8.8–16.3),] than patients with low or no ERCC1 production [median OS: 21.4 months, mean OS ± SE: 37.9 months ±10 (95% CI: 18.3–57.5)] (p = 0.006). OS, Overall Survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us